ArticleInternational journal of women's health2025
Study on Differential Metabolites Between Human Papillomavirus Infection and Cervical Cancer Based on Non-Targeted Metabolomics.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteomic and Metabolomic Analyses of HPV-Positive High-Grade Squamous Intraepithelial Lesions.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the difference of metabolites between human papillomavirus (HPV) infection and the occurrence and development of cervical cancer based on non-targeted metabolomics. Methods: Between August 2022 and August 2023, 20 women of childbearing age at the Third Affiliated Hospital of Kunming Medical University, including the HPV-negative control, LSIL (HPV infection), HSIL (cervical intraepithelial neoplasia [CIN2-3]), and cervical cancer groups, were selected as research participants. Ultra-high-performance liquid chromatography and SCIEX mass spectrometry (TripleTOF 6600+, USA) were used to separate and detect the metabolites. Results: According to the results of the differential metabolite analysis, the KEGG pathway was enriched. The most obvious enrichment pathway in the CIN2-3 group compared with the HPV-negative and HPV-positive groups was the steroid hormone pathway; the most obvious enrichment pathway in the cervical cancer group compared with the HPV-negative group was the steroid hormone pathway. Compared with HPV-negative group, the most obvious enrichment pathway in the CIN2-3 group was the glycerophosphate metabolism pathway. Compared with CIN2-3 and HPV-positive group, the most obvious enrichment pathway in the cervical cancer group was the sphingolipid metabolism pathway, followed by the steroid biosynthesis and amino sugar and nucleotide metabolism pathways. Compared with the HPV-negative group, the most obvious enrichment pathway in the cervical cancer group was the steroid biosynthesis pathway, followed by the sphingolipid metabolism pathway. 19-Hydroxytestosterone is involved in the synthesis of steroid hormones. Cerebroside B is involved in sphingolipid metabolism. Potassium acetate is involved in protein digestion and absorption. Methylarsonate is involved in chemical carcinogenesis - reactive oxygen species. Conclusion: The expression levels of 19-Hydroxytestosterone, cerebroside B, potassium acetate and methylarsonate are downregulated with the aggravation of cervical lesions and can be used as potential tumor markers for cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.